ADAMAS PHARMACEUTICALS INC's ticker is ADMS and the CUSIP is 00548A106. A total of 87 filers reported holding ADAMAS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $107,000 | -29.1% | 20,995 | -0.7% | 0.00% | – |
| Q1 2019 | $151,000 | -6.2% | 21,149 | +12.5% | 0.00% | – |
| Q4 2018 | $161,000 | -52.2% | 18,796 | +11.9% | 0.00% | – |
| Q3 2018 | $337,000 | -63.2% | 16,795 | -52.7% | 0.00% | -100.0% |
| Q2 2018 | $917,000 | +43.3% | 35,507 | +32.8% | 0.00% | 0.0% |
| Q1 2018 | $640,000 | -25.5% | 26,743 | +5.6% | 0.00% | 0.0% |
| Q4 2017 | $859,000 | +23.2% | 25,335 | -22.9% | 0.00% | 0.0% |
| Q3 2017 | $697,000 | +152.5% | 32,878 | +95.5% | 0.00% | – |
| Q3 2016 | $276,000 | -48.1% | 16,817 | -52.1% | 0.00% | -100.0% |
| Q2 2016 | $532,000 | -15.8% | 35,116 | -19.6% | 0.00% | 0.0% |
| Q1 2016 | $632,000 | +191.2% | 43,682 | +470.0% | 0.00% | – |
| Q4 2015 | $217,000 | -23.3% | 7,664 | -54.7% | 0.00% | – |
| Q3 2015 | $283,000 | -40.2% | 16,914 | -6.3% | 0.00% | – |
| Q2 2015 | $473,000 | – | 18,053 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,601,351 | $43,963,000 | 9.03% |
| Granite Point Capital Management, L.P. | 256,031 | $4,327,000 | 3.45% |
| Opaleye Management Inc. | 285,000 | $4,817,000 | 2.84% |
| Brenner West Capital Advisors | 1,221,463 | $20,643,000 | 2.28% |
| ARMISTICE CAPITAL, LLC | 536,000 | $9,058,000 | 2.14% |
| NEXTHERA CAPITAL LP | 151,670 | $2,563,000 | 1.50% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 185,234 | $3,130,000 | 1.41% |
| Cheyne Capital Management (UK) LLP | 144,765 | $2,448,000 | 1.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 270,000 | $4,563,000 | 1.16% |
| Mosaic Family Wealth, LLC | 123,314 | $2,084,000 | 0.96% |